HIV is a serious infection, but it is no longer the death sentence it was in the 1980s and 1990s. With modern treatment, a person diagnosed with HIV today can expect to live nearly as long as someone without the virus. The key factor that determines how serious HIV becomes is whether it’s treated. On treatment, HIV is a manageable chronic condition. Left untreated, it still progresses to AIDS and can be fatal.
How HIV Has Changed Over Four Decades
Between 1981 and 1990, more than 100,000 people in the United States died of HIV/AIDS. By 1989, it was the second leading cause of death among men ages 25 to 44. The peak of global HIV deaths came in 2004, when the virus was killing roughly 2 million people a year worldwide.
The picture today is dramatically different. The U.S. age-adjusted death rate dropped from 16.2 per 100,000 in 1995 to 1.4 per 100,000 in 2019. Globally, HIV-related deaths fell 70% from that 2004 peak, down to an estimated 630,000 in 2024. That number is still significant, and most of those deaths occur in places where people lack access to treatment. But in settings where treatment is available, an HIV diagnosis has shifted from a crisis to a condition people live with for decades.
What Happens Without Treatment
Untreated HIV progresses through three stages. The first is acute infection, which occurs in the weeks after exposure. Many people experience flu-like symptoms during this phase: fever, fatigue, sore throat, swollen lymph nodes. The virus replicates rapidly during this window.
The second stage is chronic HIV infection, sometimes called clinical latency. The virus is still active but reproducing at lower levels. People in this stage may feel fine and have no symptoms for years. Without treatment, this phase typically lasts about a decade before the immune system weakens enough to reach the third stage.
That third stage is AIDS. It’s defined by a specific threshold: when immune cells called CD4 cells drop below 200 per cubic millimeter of blood (a healthy count is usually between 500 and 1,500). At that point, the immune system is too damaged to fight off infections that a healthy body would handle easily. These are called opportunistic infections, and they include fungal lung infections like pneumocystis pneumonia, tuberculosis, toxoplasmosis (a parasite that can infect the brain), and severe fungal infections of the mouth and throat. Without treatment, a person with AIDS typically survives about three years.
How Treatment Changes the Outcome
Antiretroviral therapy, or ART, is a combination of medications (usually two to four) that stop HIV from copying itself inside your cells. Each drug blocks the virus at a different point in its replication cycle. Some prevent it from entering cells. Others stop it from inserting its genetic instructions. Others block the assembly of new virus particles. Used together, they reduce the amount of virus in the body to levels so low that standard blood tests can’t detect it, typically fewer than 20 copies of HIV per milliliter of blood.
This state, called viral suppression, is the goal of treatment. When someone reaches and maintains it, their immune system can recover and function close to normal. Life expectancy for people with HIV on effective treatment now falls only a few years short of the general population in many settings. The gap continues to narrow as newer medications become more effective and cause fewer side effects.
Viral suppression also eliminates the risk of passing HIV to sexual partners. This principle, known as Undetectable = Untransmittable (U=U), is backed by large clinical studies and endorsed by the CDC. A person living with HIV who maintains an undetectable viral load has zero risk of sexually transmitting the virus. That finding has reshaped both public health strategy and the daily lives of people with HIV.
Long-Term Health Risks That Remain
Living longer with HIV does mean managing some health risks that go beyond the virus itself. Even with successful treatment, HIV creates low-level chronic inflammation in the body that accelerates certain aging-related conditions. These aren’t the dramatic, life-threatening infections of untreated AIDS, but they do require ongoing monitoring.
The most significant is cardiovascular disease. People with HIV have roughly twice the risk of developing heart and artery disease compared to people without HIV, and they tend to develop it about a decade earlier. A large clinical trial found that a cholesterol-lowering statin reduced major cardiovascular events by 35% over five years in people with HIV ages 40 to 75, which has shifted treatment guidelines toward earlier use of preventive heart medications in this group.
Bone health is another concern. People with HIV have about 1.5 times the overall risk of fractures and four times the risk of hip fractures compared to the general population. Some of this excess risk comes from the virus itself and some from certain HIV medications that affect bone density. Doctors now recommend bone density screening for men over 50 and postmenopausal women with HIV, and they may adjust medications if bone loss becomes a concern.
Other areas that need attention include kidney function, liver health, metabolic conditions like diabetes, and cognitive health. A syndrome similar to frailty, characterized by loss of muscle mass, decreased energy, and reduced physical strength, appears more often and at younger ages in people with HIV. It’s linked to higher rates of falls, fractures, heart disease, and hospitalization. All of this underscores that while HIV is no longer a fatal diagnosis, it requires consistent medical care and lifestyle management over a lifetime.
The Real Dividing Line: Access to Treatment
The seriousness of HIV in 2024 depends almost entirely on one variable: whether a person gets and stays on treatment. In countries with strong healthcare systems, an HIV diagnosis at age 20 or 30 means adjusting to a daily medication regimen and attending regular checkups, not facing a shortened life. Most people on treatment take one or two pills a day, and long-acting injectable options now allow some people to receive treatment as infrequently as every two months.
The 630,000 people who still die of HIV-related causes each year, including 75,000 children, overwhelmingly live in regions where treatment access remains limited. Globally, HIV-related deaths have dropped 54% since 2010, but the progress is uneven. The virus remains a serious global health challenge, not because effective treatment doesn’t exist, but because it hasn’t reached everyone who needs it.
For an individual who tests positive and starts treatment promptly, HIV is a serious but manageable condition. It demands lifelong medication, regular monitoring, and attention to the cardiovascular and bone health risks that come with chronic inflammation. But it no longer defines or shortens a life the way it did a generation ago.